The HDAC inhibitor SAHA is currently used for treating triple negative breast cancer TNBC patients52, and the drug CT20p, which targets the CCT complex, is currently being investigated for its therapeutic potential for lung and breast cancer treatment53,54. Here, FLVCR2 is linked to triple-negative breast carcinoma.